14-day Premium Trial Subscription Sign Up For FreeGet Free

BioMarin Pharmaceutical Inc. Stock Forecast NASDAQ:BMRN

Price Target and Analyst Ratings

Most Recent Rating

On September 14, 2021 "SVB Leerink" gave "" rating for BMRN. The price target was set to $77.98.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-14 Reiterated by SVB Leerink $76.17 $77.98
2021-09-09 $86.00 - $96.00 Upgraded by Stifel Nicolaus $80.11 $76.70→1.4%
2021-09-07 $88.00 Reiterated by Royal Bank of Canada $77.81 $78.57→7.5%
2021-09-07 $152.00 Reiterated by Wedbush $77.81 $78.57→7.5%
2021-08-30 $141.00 - $152.00 Target Raised by Wedbush $83.27 $83.46→0.1%
2021-07-29 $141.00 Reiterated by Wedbush $78.51 $80.22+1.9%
2021-07-29 $112.00 Initiated by Jefferies Financial Group $78.51 $80.22+1.9%
2021-07-29 $87.00 - $88.00 Target Raised by Royal Bank of Canada $78.51 $81.07+3.0%
2021-07-29 $112.00 - $119.00 Target Raised by Piper Sandler $78.51 $78.73+0.5%
2021-07-16 $141.00 Reiterated by Wedbush $78.84 $79.53→0.1%
2021-07-11 Initiated by SVB Leerink $83.62 $83.62+0.8%
2021-07-02 Reiterated by SVB Leerink $85.47 $83.62+0.8%
2021-07-02 Buy Reiterated by SVB Leerink $85.47
2021-06-29 Buy Reiterated by Wedbush $83.46 $141.00
2021-04-28 Buy Reiterated by Wedbush $80.46 $139.00
2021-04-26 Outperform Initiated by Credit Suisse Group $81.16 $102.00
2021-04-26 Equal Weight Target Lowered by Morgan Stanley $81.16 $85.00 → $82.00
2021-04-19 Equal Weight Target Lowered by Morgan Stanley $79.59 $85.00 → $82.00
2021-03-23 Outperform Reiterated by Wedbush $76.52 $139.00
2021-03-08 In-Line - Outperform Upgraded by Evercore ISI $76.59 $90.00 → $100.00
2021-03-08 Buy Target Lowered by Canaccord Genuity $76.59 $95.00 → $91.00
2021-03-01 Buy Target Lowered by Canaccord Genuity $79.17 $95.00 → $91.00
2021-03-01 Outperform Upgraded by Evercore ISI $79.17
2021-03-01 Buy Reiterated by Robert W. Baird $79.17
2021-01-11 Positive - Outperform Target Raised by Robert W. Baird $81.24 $100.00 → $110.00
2020-11-06 Outperform Target Lowered by SVB Leerink $76.74 $113.00 → $108.00
2020-09-10 Buy Reiterated by Wedbush $71.87
2020-09-10 Target Lowered by Truist $71.87 $130.00 → $125.00
2020-08-21 Equal Weight Target Lowered by Morgan Stanley $75.03 $125.00 → $85.00
2020-08-20 Target Lowered by Oppenheimer $74.85 $116.00 → $88.00
2020-08-20 Target Lowered by Truist $74.85 $143.00 → $130.00
2020-08-20 Outperform - Market Perform Reiterated by William Blair $74.85
2020-08-20 Buy Target Lowered by Canaccord Genuity $74.85 $119.00 → $95.00
2020-08-20 Buy Target Lowered by Jefferies Financial Group $74.85 $138.00 → $118.00
2020-08-19 Buy - Neutral Downgraded by Citigroup $76.72
2020-08-19 Buy - Hold Downgraded by Stifel Nicolaus $76.72 $127.00 → $100.00
2020-08-19 Outperform Target Lowered by SVB Leerink $76.72 $140.00 → $113.00
2020-08-19 Buy Reiterated by Wedbush $76.72 $136.00
2020-08-19 Outperform - Sector Perform Downgraded by Royal Bank of Canada $76.72
2020-08-14 Target Raised by Goldman Sachs Group $118.16 $172.00 → $218.00
2020-08-06 Market Perform Target Raised by BMO Capital Markets $119.65 $94.00 → $108.00
2020-08-05 Hold Initiated by Oppenheimer $119.83 $116.00
2020-08-05 Buy Reiterated by Wedbush $119.83 $146.00
2020-08-05 Target Raised by Piper Sandler $119.83 $120.00 → $133.00
2020-08-05 Target Raised by Barclays $119.83 $125.00 → $135.00
2020-08-05 Buy Reiterated by Credit Suisse Group $119.83 $128.00
2020-08-05 Overweight Target Raised by JPMorgan Chase & Co. $119.83 $140.00 → $156.00
2020-08-05 Outperform Target Raised by SVB Leerink $119.83 $130.00 → $140.00
2020-07-28 Buy Reiterated by JPMorgan Chase & Co. $122.83 $140.00
2020-07-27 Buy Reiterated by Wedbush $124.00
2020-07-08 Overweight - Equal Weight Downgraded by Morgan Stanley $128.73 $125.00
2020-07-06 Buy Target Raised by Citigroup $127.71 $105.00 → $148.00
2020-06-21 Buy Reiterated by JPMorgan Chase & Co. $124.12
2020-06-18 Performer Target Raised by Oppenheimer $113.83 $88.00 → $95.00
2020-06-18 Buy Reiterated by Wedbush $113.83 $145.00
2020-06-10 Buy Target Raised by Bank of America $107.66 $120.00 → $130.00
2020-06-05 Target Raised by Barclays $105.80 $105.00 → $125.00
2020-06-01 Buy Reiterated by Credit Suisse Group $107.39 $128.00
2020-05-10 Buy Reiterated by Cfra $95.20 $115.00
2020-05-08 Target Raised by Canaccord Genuity $95.20 $108.00 → $119.00
2020-05-07 Buy Reiterated by Credit Suisse Group $92.00 $128.00
2020-05-01 Buy Reiterated by William Blair $88.12
2020-05-01 Buy Reiterated by Canaccord Genuity $88.12 $108.00
2020-05-01 Outperform Reiterated by Wedbush $88.12 $145.00
2020-04-30 Hold Reiterated by Oppenheimer $92.02 $88.00
2020-04-30 Outperform Target Lowered by Credit Suisse Group $92.02 $131.00 → $128.00
2020-04-30 Buy Target Lowered by SunTrust Banks $92.02 $110.00 → $109.00
2020-04-30 Hold Reiterated by Nomura $92.02 $77.00

BMRN Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -5.50% during the next 3 months and, with a 90% probability hold a price between $69.11 and $79.66 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-22 $73.06 $78.64 $84.22
2021-09-23 $72.98 $78.56 $84.14
2021-09-24 $72.90 $78.48 $84.06
2021-09-27 $72.82 $78.40 $83.98
2021-09-28 $72.74 $78.32 $83.90
2021-09-29 $72.67 $78.25 $83.83
2021-09-30 $72.59 $78.17 $83.75
2021-10-01 $72.51 $78.09 $83.67
2021-10-04 $72.43 $78.01 $83.59
2021-10-05 $72.36 $77.93 $83.51
2021-10-06 $72.28 $77.86 $83.44
2021-10-07 $72.20 $77.78 $83.36
2021-10-08 $72.12 $77.70 $83.28
2021-10-11 $72.04 $77.62 $83.20
2021-10-12 $71.97 $77.55 $83.12
2021-10-13 $71.89 $77.47 $83.05
2021-10-14 $71.81 $77.39 $82.97
2021-10-15 $71.73 $77.31 $82.89
2021-10-18 $71.65 $77.23 $82.81
2021-10-19 $71.58 $77.16 $82.74
2021-10-20 $71.50 $77.08 $82.66
2021-10-21 $71.42 $77.00 $82.58
2021-10-22 $71.34 $76.92 $82.50
2021-10-25 $71.26 $76.84 $82.42
2021-10-26 $71.19 $76.77 $82.35
2021-10-27 $71.11 $76.69 $82.27
2021-10-28 $71.03 $76.61 $82.19
2021-10-29 $70.95 $76.53 $82.11
2021-11-01 $70.88 $76.45 $82.03
2021-11-02 $70.80 $76.38 $81.96

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary syn... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT